In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 126 to 150 of 303

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Inhaled treprostinil for treating pulmonary hypertension caused by interstitial lung disease ID6459	Technology appraisal guidance	TBC
Insulin icodec for treating type 2 diabetes [ID6175]	Technology appraisal guidance	TBC
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance	TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]	Technology appraisal guidance	TBC
Iptacopan for treating complement 3 glomerulopathy ID6283	Technology appraisal guidance	TBC
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981	Technology appraisal guidance	16 July 2025
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]	Technology appraisal guidance	TBC
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]	Technology appraisal guidance	TBC
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 [ID1336]	Technology appraisal guidance	TBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]	Technology appraisal guidance	TBC
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]	Technology appraisal guidance	5 February 2025
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]	Technology appraisal guidance	TBC
Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]	Technology appraisal guidance	TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]	Technology appraisal guidance	TBC
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166]	Technology appraisal guidance	TBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]	Technology appraisal guidance	TBC
Lifileucel for previously treated unresectable or metastatic melanoma ID3863	Technology appraisal guidance	TBC
Linzagolix for treating symptoms of endometriosis [ID6357]	Technology appraisal guidance	25 June 2025
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174]	Technology appraisal guidance	TBC
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable [ID3887]	Technology appraisal guidance	TBC
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]	Technology appraisal guidance	TBC
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434]	Technology appraisal guidance	30 April 2025
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]	Technology appraisal guidance	TBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]	Technology appraisal guidance	TBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340	Technology appraisal guidance	TBC

Results per page

10
25
50
All